HYDRAZINE SULFATE

[Guest guest]

http://scri.ngen.com/

 

 

HYDRAZINE SULFATE

 

" ...Since hydrazine sulfate provided relief of a wide spectrum of

cancer symptoms, it may be recommended for patients with end-stage

cancer. "

 

" ...virtually no significant untoward side effects... "

 

 

 

The Syracuse Cancer Research Institute is a charitable, educational

and scientific organization, tax-exempt under section 501©(3) of the

Internal Revenue Code. SCRI expense distribution averages 92% for

research, 4% for fund raising and 4% for management and general. For a

copy of our Annual Report, write: Attorney General, Charities Bureau,

120 Broadway, New York, NY 10271; or Syracuse Cancer Research

Institute, 600 East Genesee Street, Syracuse, NY 13202.

 

The Syracuse Cancer Research Institute does not receive any funds in

regard to its hydrazine sulfate activities and does not market, sell

or distribute this drug. The institute is wholly dependent for its

funding on contributions from the public—from foundations, business

and industry and concerned individuals—and asks your help in

sustaining its life-expanding programs. Your tax-deductible

contributions are vital to this effort and serve to enhance the

welfare and lives of cancer patients everywhere.

 

All gifts will be promptly acknowledged and can be sent to:

Syracuse Cancer Research Institute

600 East Genesee Street

Syracuse, NY 13202

GENERAL INFORMATION

 

Hydrazine sulfate is an anti-cachexia drug which acts to reverse the

metabolic processes of debilitation and weight loss in cancer and

secondarily acts to stabilize or regress tumors. Every

informed-consent, controlled clinical trial performed in accordance

with internationally accepted standards of scientific conduct—without

exception—has indicated efficacy and safety of the drug. The only

contrary results, discussed below, have been the National Cancer

Institute-sponsored studies, in which incompatible agents

(medications) were used with the test drug. (The use of incompatible

agents, in violation of the foregoing standards, acts to cause a

negative study.)

 

Hydrazine sulfate is a monoamine oxidase (MAO) inhibitor and is

incompatible with tranquilizers, barbiturates, alcohol and other

central nervous system depressants. Foods high in tyramine, such as

aged cheese and fermented products, are also incompatible with MAO

inhibitors. The use of tranquilizers, barbiturates and/or alcoholic

beverages with hydrazine sulfate destroys the efficacy of this drug

and represents a clear clinical hazard.

 

The U.S. National Cancer Institute-published studies of hydrazine

sulfate (Journal of Clinical Oncology, June 1994), which were reported

as negative, denied the concurrent use of tranquilizers in general.

However, under pressure of an investigation of the NCI-sponsored

studies by the U.S. General Accounting Office ordered by Congress, the

NCI admitted to the widespread use of both phenothiazine and the more

powerful benzodiazepine tranquilizers—in 94% of all patients tested

(Journal of Clinical Oncology, June 1995). Approximately half of these

patients were administered these tranquilizers on a long-term basis,

and some on a continual basis. It was further stated by the NCI that

concomitant drug use—tranquilizers, alcohol, barbiturates, etc.—was

not computerized and patient records of such drug use were " incomplete. "

 

Hydrazine sulfate has been demonstrated to produce only few and

transient side effects. There have been no instances of bone-marrow

depression or of heart, lung or immune system toxicity. Hydrazine

sulfate has never been shown to be carcinogenic—i.e., cause cancer—in

humans.

 

In its December 4, 2000 issue the respected medical journal Annals of

Internal Medicine published a " Brief Communication " and editorial—in

its journal and on the Internet—alleging " fatal hepatorenal failure "

in a single patient due to hydrazine sulfate. However, there was no

proof presented that the patient in question ever took hydrazine

sulfate. The authors of the " Brief Communication " stated: " We could

not obtain samples of the product he [the patient] ingested for

laboratory analysis. " This means that there was no possibility of a

direct examination of what it was the patient was taking. The authors

further stated: " His blood was not tested for the presence of

hydrazine. " But there are simple spectrofluorometric blood tests that

can confirm even the tiniest residues of hydrazine sulfate ingested

even months prior.

 

It must be stressed that no medical journal anywhere—of high repute or

not—would publish an article and editorial based on only one case,

calling attention of the medical and lay public to the potential

toxicity of a drug gaining in common use, without incontrovertible,

verifiable, iron-clad proof that the patient in question ever took the

drug in the first place. No journal would have the ethical

recklessness to publish an article having far-reaching repercussions

on the public health, without absolute proof of its basic, fundamental

assumptions.

 

The authors of the article and editorial, basing their warning of

hydrazine sulfate toxicity to the liver and kidney on but one

unverifiable patient, were nevertheless conversant with the

large-scale National Cancer Institute-sponsored studies of hydrazine

sulfate—in which hundreds of patients verifiably received the

drug—which showed the complete absence of any organ toxicity,

including liver and kidney: " There were no significant differences

between the protocol treatment arms [hydrazine sulfate and placebo]

with regard to myelodepression, gastrointestinal toxicity, renal

toxicity, cardiopulmonary toxicity or neurotoxicity. "

 

(Contrast this situation—in which a cancer " drug alert " is

disseminated worldwide via the Internet based on unconfirmed use in a

single patient—with the tens of thousands of authenticated drug deaths

due to cancer chemotherapy each year. Yet no medical journal has seen

fit to issue an Internet warning to the public of this truly

legitimate hazard.)

 

Hydrazine sulfate has been in clinical use since 1973. Thousands of

study patients have been published in the medical literature. And many

more thousands the world over have been treated by their individual

doctors. There has not been a single case of hepatorenal failure ever

reported.

 

The Syracuse Cancer Research Institute therefore judges that the " drug

alert " issued by the Annals of Internal Medicine in December 2000, in

regard to hydrazine sulfate, is simply not credible.

 

For a comprehensive discussion of hydrazine sulfate, please visit

www.hydrazinesulfate.org, as given on the left border of the present

Web site ( " The Truth About Hydrazine Sulfate—Dr. Gold Speaks " )

THE ELWOOD FUND

 

Elwood was a beloved seventeen-year-old cat who passed away June 16,k

2005, of kidney failure. A sleek, short-hair female cat, Elwood made

medical history and was responsible for the betterment of thousands of

cats and dogs around the world. In 1997 Elwood had part of her stomach

removed at Cornell University Veterinary Hospital for cancer; however,

the edges sewn together were full of cancer and she was not expected

to live long. She returned to the clinic six weeks later emaciated.

She was placed on a course of chemotherapy to be given every three

weeks and on daily hydrazine sulfate, an anticancer drug developed by

the Syracuse Cancer Research Institute, and was given a prognosis of

" two to five months. " The chemotherapy was discontinued after the

second course because of side effects, and Elwood was maintained only

on daily hydrazine sulfate. After the chemotherapy was discontinued,

Elwood began to nibble, then eat vigorously. Until then, the

longest-lived cat on record with her disease was one year. After one

year, Elwood had regained all her lost weight, having been maintained

only on daily hydrazine sulfate (and a steroid), and visited the

clinic every six months for the next eight years. Word of her recovery

spread throughout the nation, as a result of which thousands of cats

and dogs were placed on hydrazine sulfate, many of whom were reported

to have recovered completely.

 

The Syracuse Cancer Research Institute has established the Elwood

Fund, dedicated to the beneficial treatment of small animals with

terminal disease, and to the dissemination of information to

veterinarians and to owners of cats and dogs in regard to the therapy

of these animals. Those wishing to contribute to the Elwood Fund are

asked to send tax-deductible contributions to the Syracuse Cancer

Research Institute, Elwood Fund, 600 E. Genesee Street, Syracuse, NY

13202. All contributions will be acknowledged.

 

For further information please call or have your health care

professional call the institute between 9:00 AM and 5:00 PM Eastern

time, weekdays, (315)472-6616, 472-6618, 472-2229.

 

This page is designed and hosted by NGEN and is the property of the

Syracuse Cancer Research Institute © 1996-2005, Syracuse Cancer

Research Institute. All rights reserved. Last modified on 16 June 2005